Adcendo ApS: Valuation, Funding & Investors
Adcendo ApS is a biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The company is advancing a clinical ADC pipeline including programs ADCE-T02 (Tissue Factor), ADCE-D01 (uPARAP), and ADCE-B05, focusing on dose escalation and expansion studies across multiple tumor indications.
Leadership & Board
- Current Number of Employees
- 68
- Current LinkedIn Followers
- 11,632
Latest Estimated Valuation
- Total Amount Raised
- $75M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $75M
- Latest Funding Round
- Series C
Employee Trend
Adcendo ApS had 68 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Adcendo ApS had 11,632 followers as of November 9, 2026. The number of followers increased by 30 (0.26%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Apr 14, 2026 | Series C | $75.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Jeito Capital | Series C |
| Vida Ventures | Series C |
| BPI France | Series C |
| EIFO | Series C |
Similar Companies
A snapshot of private companies similar to Adcendo ApS, helping you discover and navigate related company profiles.







